Clinical Trial Update: Subcutaneous Immunoglobulin for Myasthenia Gravis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating subcutaneous immunoglobulin for Myasthenia Gravis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Subcutaneous immunoglobulin (immunoglobulin)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Myasthenia Gravis | Phase 2 | Status: COMPLETED